Arginine functionalization of hydrogels for heparin binding-a supramolecular approach to developing a pro-angiogenic biomaterial

Biotechnology and Bioengineering

Volumn 110, Issue 1, 2013, Pages 296-317

  Gilmore, Louisa ^a   Rimmer, Stephen ^a   Mcarthur, Sally L ^b   Mittar, Shweta ^a   Sun, Dachau ^a   Macneil, Sheila ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Angiogenesis; Heparin; Hydrogels

Indexed keywords

ARGININE; BIOLOGICAL MATERIALS; BIOMATERIALS; CARBOXYLIC ACIDS; GLYCOLS; PEPTIDES; POLYSACCHARIDES; TISSUE ENGINEERING;

ACRYLIC ACIDS; ALLYL CARBONATES; ANGIOGENESIS; CARBOXYLIC ACID GROUPS; CYTOCOMPATIBILITY; DIETHYLENE GLYCOL; FUNCTIONALIZATIONS; FUNCTIONALIZED; HEPARIN; HEPARIN BINDING; HUMAN DERMAL FIBROBLASTS; IN-VITRO; MICROVASCULAR ENDOTHELIAL CELLS; OLIGOARGININE; POSITIVELY CHARGED PEPTIDES; TISSUE ENGINEERING APPLICATIONS; VASCULAR ENDOTHELIAL GROWTH FACTOR;

HYDROGELS;

ACRYLIC ACID; AMINO ACID DERIVATIVE; ARGININE; BIOMATERIAL; CARBOXYLIC ACID; DIETHYLENE GLYCOL; DIETHYLENE GLYCOL BISALLYL CARBONATE; HEPARIN; MONOMER; N VINYL 2 PYROLIDONE; OLIGOARGININE; OLIGOLYSINE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 165;

ANGIOGENESIS; ARTICLE; BINDING KINETICS; BIOCOMPATIBILITY; CELL ADHESION; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CHEMICAL MODIFICATION; CONTROLLED STUDY; FLUORESCENCE SPECTROSCOPY; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROGEL; IN VITRO STUDY; MICROVASCULAR ENDOTHELIAL CELL; PEPTIDE SYNTHESIS; POLYMERIZATION; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; SKIN FIBROBLAST; SUPRAMOLECULAR CHEMISTRY; TISSUE ENGINEERING; X RAY PHOTOELECTRON SPECTROSCOPY;

EID: 84869863010     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.24598     Document Type: Article

References (47)

1. Benoit DSW. 2005. Heparin functionalized PEG gels that modulate protein adsorption for hMSC adhesion and differentiation. Acta Biomater 1: 461-470.
2. Chen YM, Tanaka M, Gong JP, Yasuda K, Yamamoto S, Shimomura M, Osada Y. 2007. Platelet adhesion to human umbilical vein endothelial cells cultured on anionic hydrogel scaffolds. Biomaterials 28(10): 1752-1760.
3. Christensen K, Larsson R, Emanuelsson H, Elgue G, Larsson A. 2005. Improved blood compatibility of a stent graft by combining heparin coating and abciximab. Thromb Res 115(3): 245-253.
4. Darland DC, D'Amore PA. 1999. Blood vessel maturation: Vascular development comes of age. J Clin Invest 103(2): 157-158.
5. Dvorak HF, Brown LF, Detmar M, Dvorak AM. 1995. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146(5): 1029-1039.
6. Eppler SM, Combs DL, Henry TD, Lopez JJ, Ellis SG, Yi JH, Annex BH, McCluskey ER, Zioncheck TF. 2002. A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther 72(1): 20-32.
7. Epstein SE, Fuchs S, Zhou YF, Baffour R, Kornowski R. 2001a. Therapeutic interventions for enhancing collateral development by administration of growth factors: Basic principles, early results and potential hazards. Cardiovasc Res 49(3): 532-542.
8. Epstein SE, Kornowski R, Fuchs S, Dvorak HF. 2001b. Angiogenesis therapy: Amidst the hype, the neglected potential for serious side effects. Circulation 104(1): 115-119.
9. Gilmore L, MacNeil S, Rimmer S. 2009. Phosphate functional core-shell polymer nanoparticles for the release of vascular endothelial growth factor. Chembiochem 10(13): 2165-2170.
10. Gitay-Goren H, Soker S, Vlodavsky I, Neufeld G. 1992. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J Biol Chem 267(9): 6093-6098.
11. Gu F, Neufeld R, Amsden B. 2007. Sustained release of bioactive therapeutic proteins from a biodegradable elastomeric device. J Control Release 117: 80-89.
12. Haigh R, Fullwood N, Rimmer S. 2002. Synthesis and properties of amphiphilic networks 2: A differential scanning calorimetric study of poly(dodecyl methacrylate-stat-2, 3 propandiol-1-methacrylate-stat-ethandiol dimethacrylate) networks and adhesion and spreading of dermal fibroblasts on these materials. Biomaterials 23(16): 3509-3516.
13. Hamma-Kourbali Y, Vassy R, Starzec A, Le Meuth-Metzinger V, Oudar O, Bagheri-Yarmand R, Perret G, Crepin M. 2001. Vascular endothelial growth factor 165 (VEGF(165)) activities are inhibited by carboxymethyl benzylamide dextran that competes for heparin binding to VEGF(165) and VEGF(165). KDR complexes. J Biol Chem 276(43): 39748-39754.
14. Haxhinasto KB, English AE, Moy AB. 2008. Equilibrium and non-equilibrium charge-dependent quantification of endothelial cell hydrogel scaffolds. J Mater Sci Mater Med 19(5): 1999-2008.
15. Heyman PW, Cho CS, McRea JC, Olsen DB, Kim SW. 1985. Heparinized polyurethanes: In vitro and in vivo studies. J Biomed Mater Res 19(4): 419-436.
16. Hopkins SP, Bulgrin JP, Sims RL, Bowman B, Donovan DL, Schmidt SP. 1998. Controlled delivery of vascular endothelial growth factor promotes neovascularization and maintains limb function in a rabbit model of ischemia. J Vasc Surg 27(5): 886-894 discussion 895.
17. Jay SM, Saltzman WM. 2008. Controlled delivery of VEGF via modulation of alginate microparticle ionic crosslinking. J Control Release 134: 26-34.
18. Jay SM, Saltzman WM. 2009. Controlled delivery of VEGF via modulation of alginate microparticle ionic crosslinking. J Control Release 134(1): 26-34.
19. Jeon O, Kang SW, Lim HW, Hyung Chung J, Kim BS. 2006. Long-term and zero-order release of basic fibroblast growth factor from heparin-conjugated poly(L-lactide-co-glycolide) nanospheres and fibrin gel. Biomaterials 27(8): 1598-1607.
20. Johansson C, Gernandt J, Bradley M, Vincent B, Hansson P. 2010. Interaction between lysozyme and colloidal poly(NIPAM-co-acrylic acid) microgels. J Colloid Interface Sci 347(2): 241-251.
21. Johansson C, Hansson P, Malmsten M. 2007. Interaction between lysozyme and poly(acrylic acid) microgels. J Colloid Interface Sci 316(2): 350-359.
22. Kanczler JM, Barry J, Ginty P, Howdle SM, Shakesheff KM, Oreffo RO. 2007. Supercritical carbon dioxide generated vascular endothelial growth factor encapsulated poly(DL-lactic acid) scaffolds induce angiogenesis in vitro. Biochem Biophys Res Commun 352(1): 135-141.
23. Kavanagh CA, Gorelova TA, Selezneva II, Rochev YA, Dawson KA, Gallagher WM, Gorelov AV, Keenan AK. 2005. Poly(N-isopropylacrylamide) copolymer films as vehicles for the sustained delivery of proteins to vascular endothelial cells. J Biomed Mater Res A 72(1): 25-35.
24. Kiick KL. 2008. Peptide- and protein-mediated assembly of heparinized hydrogels. Soft Matter 4: 29-37.
25. Kim SW, Jacobs H. 1996. Design of nonthrombogenic polymer surfaces for blood-contacting medical devices. Blood Purif 14(5): 357-372.
26. Kim S, English AE, Kihm KD. 2009. Surface elasticity and charge concentration-dependent endothelial cell attachment to copolymer polyelectrolyte hydrogel. Acta Biomater 5(1): 144-151.
27. Kipshidze N, Chekanov V, Chawla P, Shankar LR, Gosset JB, Kumar K, Hammen D, Gordon J, Keelan MH. 2000. Angiogenesis in a patient with ischemic limb induced by intramuscular injection of vascular endothelial growth factor and fibrin platform. Tex Heart Inst J 27(2): 196-200.
28. Klagsbrun M, D'Amore PA. 1996. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 7(3): 259-270.
29. Laham RJ, Sellke FW, Edelman ER, Pearlman JD, Ware JA, Brown DL, Gold JP, Simons M. 1999. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: Results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 100(18): 1865-1871.
30. Lamalice L, Le Boeuf F, Huot J. 2007. Endothelial cell migration during angiogenesis. Circ Res 100(6): 782-794.
31. Lazarous DF, Shou M, Scheinowitz M, Hodge E, Thirumurti V, Kitsiou AN, Stiber JA, Lobo AD, Hunsberger S, Guetta E, Epstein SE, Unger EF. 1996. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation 94(5): 1074-1082.
32. MacNeil S. 2007. Progress and opportunities for tissue-engineered skin. Nature 445(7130): 874-880.
33. Norton LW, Tegnell E, Toporek SS, Reichert WM. 2005. In vitro characterization of vascular endothelial growth factor and dexamethasone releasing hydrogels for implantable probe coatings. Biomaterials 26: 3285-3297.
34. Nuttelman CR, Mortisen DJ, Henry SM, Anseth KS. 2001. Attachment of fibronectin to poly(vinyl alcohol) hydrogels promotes NIH3T3 cell adhesion, proliferation, and migration. J Biomed Mater Res A 57(2): 217-223.
35. Park KD, Okano T, Nojiri C, Kim SW. 1988. Heparin immobilization onto segmented polyurethane-urea surfaces-effect of hydrophilic spacers. J Biomed Mater Res 22(11): 977-992.
36. Pike DB, Cai S, Pomraning KR, Firpo MA, Fisher RJ, Shu XZ, Prestwich GD, Peattie RA. 2006. Heparin-regulated release of growth factors in vitro and angiogenic response in vivo to implanted hyaluronan hydrogels containing VEGF and bFGF. Biomaterials 27(30): 5242-5251.
37. Rimmer S, Johnson C, Zhao B, Collier J, Gilmore L, Sabnis S, Wyman P, Sammon C, Fullwood NJ, MacNeil S. 2007. Epithelialization of hydrogels achieved by amine functionalization and co-culture with stromal cells. Biomaterials 28(35): 5319-5331.
38. Rouet V, Hamma-Kourbali Y, Petit E, Panagopoulou P, Katsoris P, Barritault D, Caruelle JP, Courty J. 2005. A synthetic glycosaminoglycan mimetic binds vascular endothelial growth factor and modulates angiogenesis. J Biol Chem 280(38): 32792-32800.
39. Schumacher B, Pecher P, von Specht BU, Stegmann T. 1998. Induction of neoangiogenesis in ischemic myocardium by human growth factors: First clinical results of a new treatment of coronary heart disease. Circulation 97(7): 645-650.
40. Smith LE, Rimmer S, MacNeil S. 2006. Examination of the effects of poly(N-vinylpyrrolidinone) hydrogels in direct and indirect contact with cells. Biomaterials 27(14): 2806-2812.
41. Soker S, Goldstaub D, Svahn CM, Vlodavsky I, Levi BZ, Neufeld G. 1994. Variations in the size and sulfation of heparin modulate the effect of heparin on the binding of VEGF165 to its receptors. Biochem Biophys Res Commun 203(2): 1339-1347.
42. Steffens GC, Yao C, Prevel P, Markowicz M, Schenck P, Noah EM, Pallua N. 2004. Modulation of angiogenic potential of collagen matrices by covalent incorporation of heparin and loading with vascular endothelial growth factor. Tissue Eng 10(9-10): 1502-1509.
43. Sun Q, Chen RR, Shen Y, Mooney DJ, Rajagopalan S, Grossman PM. 2005. Sustained vascular endothelial growth factor delivery enhances angiogenesis and perfusion in ischemic hind limb. Pharm Res 22(7): 1110-1116.
44. Takeshita S, Zheng LP, Brogi E, Kearney M, Pu LQ, Bunting S, Ferrara N, Symes JF, Isner JM. 1994. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 93(2): 662-670.
45. Xu FJ, Li YL, Kang ET, Neoh KG. 2005. Heparin-coupled poly(poly(ethylene glycol) monomethacrylate)-Si(111) hybrids and their blood compatible surfaces. Biomacromolecules 6(3): 1759-1768.
46. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. 1991. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64(4): 841-848.
47. Yoon JJ, Chung HJ, Park TG. 2007. Photo-crosslinkable and biodegradable pluronic/heparin hydrogels for local and sustained delivery of angiogenic growth factor. J Biomed Mater Res A 83(3): 597-605.